Neurodegenerative disorders are common among the elderly. They possess a
tremendous therapeutic challenge for drug development and tackling the
disease. Alzheimer's ranks as the most common neurodegenerative disease
affecting the elderly population. Developing therapeutics is still a
challenge despite advancements in the medical sciences. Replacing the
small molecules that are used for Alzheimer's today, numerous Monoclonal
antibodies and vaccines are tried that targets explicitly the disease
pathology, either beta-amyloid or Tau aggregation. In this review, we
try to shed light on the existing small molecule therapeutics and the
recent advances with insights into Monoclonal antibodies and clinical
trials.